SIGA's tecovirimat fails mpox lesion resolution endpoint; STOMP enrollment stopped

SIGA TECHNOLOGIES INC

Tecovirimat did not improve time to lesion resolution vs placebo in mild to moderate clade II mpox; DSMB recommended stop enrollment.
Enrollment halted in all study arms including open-label for severe patients; data analysis ongoing for secondary endpoints.
Safety profile affirmed as comparable to placebo, consistent with prior studies over 15 years.
CEO stated ~75% of randomized patients received drug >5 days after symptom onset; early treatment may offer benefit.
Company expects three ongoing trials (UNITY, Platinum-CAN, EPOXI) to yield similar results given design parallels.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.